Zoekresultaten - 4 results
A Comparative Immunogenicity and Safety Trial of Two Different Schedules of Single-visit Intradermal Rabies Post-exposure Vaccination Following a Single-visit Pre-exposure Vaccination.
for immunogenicity was the percentage of subjects with an adequate antibody level (>0.5 IU /mL) seven days after the booster doses. The safety endpoint was the proportion of participants developing ...
Inhibition of MALT1 decreases neuroinflammation and pathogenicity of virulent rabies virus in mice.
had no effect. Disease development was also delayed in mice treated with the MALT1 protease inhibitor mepazine, and in knock-in mice expressing a catalytically inactive MALT1 mutant protein, showing an ...
Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days.
with an adequate antibody level >0.5 IU /mL seven days after the booster injection. The safety endpoint was the proportion of participants developing adverse reactions following the primary ...
Rabies antibody response after two intradermal pre-exposure prophylaxis immunizations: An observational cohort study.
aim of this study was to examine whether adequate rabies antibody titers are reached after two intradermal (ID) doses of rabies vaccine, with a seven-day window. METHOD: We conducted an observational ...